Blomqvist Soile, Savolainen Carita, Laine Pia, Hirttiö Päivi, Lamminsalo Elisa, Penttilä Eija, Jöks Silver, Roivainen Merja, Hovi Tapani
Department of Microbiology, Enterovirus Laboratory, National Public Health Institute (KTL), 00300 Helsinki, Finland.
J Virol. 2004 May;78(9):4876-83. doi: 10.1128/jvi.78.9.4876-4883.2004.
Two types of vaccine-derived polioviruses have been recently designated to emphasize the different origins of the evolved viruses: circulating vaccine-derived polioviruses (cVDPV) associated with outbreaks of paralytic disease and strains isolated from chronically infected immunodeficient individuals (iVDPV). We describe here a type 3 VDPV (PV3/EST/02/E252; later E252) isolated from sewage collected in Tallinn, Estonia, in October 2002. Due to aberrant properties in subtyping, the virus was subjected to detailed characterization. Partial genomic sequencing suggested that the closest relative was the oral vaccine strain PV3/Sabin, but the two virus strains shared only 86.7% of the 900 nucleotides (nt) coding for the capsid protein VP1. Phylogenetic analysis of the nearly complete genome [nt 19 to poly(A)] revealed multiple nucleotide substitutions throughout the genome and a possible Sabin 3/Sabin 1-recombination junction site in the 2C coding region. A calculation based on the estimated mutation frequency of the P1 region of polioviruses suggested that the E252 virus might have replicated in one or more individuals for approximately 10 years. No persons chronically excreting poliovirus are known in Estonia. Amino acid substitutions were seen in all known antigenic sites, which was consistent with the observed aberrant antigenic properties of the virus demonstrated by both monoclonal antibodies and human sera from vaccinated children. In spite of the apparent transmission potential, no evidence was obtained for circulation of the virus in the Estonian population.
最近指定了两种疫苗衍生脊髓灰质炎病毒,以强调进化病毒的不同起源:与麻痹性疾病暴发相关的循环疫苗衍生脊髓灰质炎病毒(cVDPV)以及从慢性感染的免疫缺陷个体中分离出的毒株(iVDPV)。我们在此描述一株于2002年10月从爱沙尼亚塔林收集的污水中分离出的3型VDPV(PV3/EST/02/E252;后称E252)。由于在亚型分型中具有异常特性,该病毒接受了详细的特征分析。部分基因组测序表明,其最接近的亲缘毒株是口服疫苗株PV3/Sabin,但这两种病毒株在编码衣壳蛋白VP1的900个核苷酸(nt)中仅共享86.7%。对近乎完整基因组[nt 19至poly(A)]的系统发育分析显示,整个基因组存在多个核苷酸替换,并且在2C编码区有一个可能的Sabin 3/Sabin 1重组连接位点。基于脊髓灰质炎病毒P1区域估计突变频率的计算表明,E252病毒可能已在一个或多个个体中复制了约10年。爱沙尼亚尚无已知长期排泄脊髓灰质炎病毒的人员。在所有已知抗原位点均发现了氨基酸替换,这与单克隆抗体和接种疫苗儿童的人血清所显示的该病毒异常抗原特性一致。尽管该病毒具有明显的传播潜力,但未获得其在爱沙尼亚人群中传播的证据。